Search Results

You are looking at 1 - 2 of 2 items for

  • Author or Editor: Carl A. Guthrie x
  • Refine by Access: All Content x
Clear All Modify Search


To evaluate effects of tilmicosin when used in fever-based and metaphylactic treatment programs to attenuate acute undifferentiated bovine respiratory disease (BRD) in cattle that recently arrived at feedlots, and to evaluate the effects of tilmicosin for the treatment of BRD.


Randomized-block controlled study.


1,639 calves from livestock auctions.


Cattle were assigned to 3 groups. Cattle in the nonmedicated (control) group were not given antibiotics during processing. Cattle in the fever-based treatment group were given tilmicosin (10 mg/kg [4.5 mg/lb] of body weight, SC) during processing when their rectal temperature was ≥ 40 C (104 F). All cattle in the metaphylactic treatment group were given tilmicosin (10 mg/kg, SC) during processing. Calves with BRD were treated with tilmicosin (10 mg/kg, SC).


Morbidity rates in the metaphylactic (30.4%) and fever-based (44.7%) treatment groups were less than that for the nonmedicated group (54.8%). Mortality rate for the metaphylactic group during the first 28 days (1.1%) and during the entire study (1.7%) was less than that for the nonmedicated group (3.3 and 4.6%, respectively). Differences were not observed in therapeutic response rates among calves with BRD that were treated.

Clinical Implications

Fever-based and metaphylactic treatment programs that used tilmicosin decreased the prevalence of BRD and improved growth of calves. Metaphylactic treatment decreased the number of fatalities caused by BRD in high-risk calves. Fever-based treatment was less effective than metaphylactic treatment for decreasing the prevalence of BRD in newly arrived cattle. (J Am Vet Med Assoc 1998,212:1919–1924)

Free access
in Journal of the American Veterinary Medical Association


Objective—To determine associations between in vitro minimum inhibitory concentrations (MICs) of tilmicosin against Mannheimia haemolytica and Pasteurella multocida and in vivo tilmicosin treatment outcome among calves with clinical signs of bovine respiratory disease (BRD).

Design—Observational, retrospective, cohort study.

Animals—976 feeder calves with clinical signs of BRD enrolled in 16 randomized clinical trials.

Procedures—Records of clinical trials from October 26, 1996, to November 15, 2004, were searched to identify calves with BRD from which a single isolate of M haemolytica or P multocida was identified via culture of deep nasal swab samples prior to treatment with tilmicosin (10 mg/kg [4.5 mg/lb], SC) and for which MICs of tilmicosin against the isolate were determined. The MICs of tilmicosin against recovered isolates and response to tilmicosin treatment were evaluated.

Results—Tilmicosin resistance among M haemolytica and P multocida isolates was uncommon (6/745 [0.8%] and 16/231 [6.9%], respectively). Treatment outcome, defined as success or failure after tilmicosin treatment, did not vary with the MIC of tilmicosin against recovered isolates. The proportion of treatment failures attributed to M haemolytica isolates categorized as resistant (MIC of tilmicosin, ≥ 32 μg/mL) or not susceptible (MIC of tilmicosin, ≥ 16 μg/mL), was 0.2% and 0.5%, respectively.

Conclusions and Clinical Relevance—Recovery of tilmicosin-resistant M haemolytica or P multocida isolates was rare, and no association was detected between MIC of tilmicosin and treatment response.

Full access
in Journal of the American Veterinary Medical Association